Penetration efficiency of antitumor agents in ovarian cancer spheroids: The case of recombinant targeted toxin DARPin-LoPE and the chemotherapy drug, doxorubicin

Evgeniya Sokolova, Olga Kutova, Alena Grishina, Anton Pospelov, Evgeniy Guryev, Alexey Schulga, Sergey Deyev, Irina Balalaeva

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

The efficiency of delivering a therapeutic agent into a tumor is among the crucial factors determining the prospects for its clinical use. This problem is particularly acute in the case of targeted antitumor agents since many of them are high-molecular-weight compounds. In this work, the penetration of therapeutic agents of two distinct molecular weights into the spheroids of ovarian adenocarcinoma overexpressing human epidermal growth factor receptor 2 (HER2) was studied. It was shown that the low-molecular-weight chemotherapy drug, doxorubicin (~0.5 kDa), effectively penetrates through almost the entire depth of a 300 to 400 µm spheroid, while the penetration depth of the HER2-specific recombinant targeted toxin, DARPin-LoPE (~42 kDa), is only a few surface layers of cells and does not exceed 70 µm. The low penetration of the targeted toxin into spheroid was shown along with a significant decrease in its efficiency against the three-dimensional tumor spheroid as compared with the two-dimensional monolayer culture. The approaches to increasing the accumulation of agents in the tumor are presented and prospects of their use in order to improve the effectiveness of therapy are discussed.

Original languageEnglish
Article number219
JournalPharmaceutics
Volume11
Issue number5
DOIs
Publication statusPublished - 1 May 2019

Keywords

  • DARPin
  • Drug penetration into tumor
  • HER2
  • Pseudomonas exotoxin A
  • Spheroid
  • Targeted therapy
  • Targeted toxin

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Penetration efficiency of antitumor agents in ovarian cancer spheroids: The case of recombinant targeted toxin DARPin-LoPE and the chemotherapy drug, doxorubicin'. Together they form a unique fingerprint.

Cite this